Home » Stocks » Denali Therapeutics

Denali Therapeutics Inc. (DNLI)

Stock Price: $40.92 USD 1.26 (3.18%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $40.73 -0.19 (-0.46%) Oct 22, 4:11 PM

Stock Price Chart

Key Info

Market Cap 4.88B
Revenue (ttm) 27.73M
Net Income (ttm) -215.81M
Shares Out 119.29M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $40.92
Previous Close $39.66
Change ($) 1.26
Change (%) 3.18%
Day's Open 39.51
Day's Range 39.44 - 41.43
Day's Volume 402,391
52-Week Range 12.39 - 45.82

More Stats

Market Cap 4.88B
Enterprise Value 4.40B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 119.29M
Float 67.09M
EPS (basic) -2.16
EPS (diluted) -2.16
FCF / Share -1.73
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.13M
Short Ratio 15.48
Short % of Float 13.60%
Beta 1.81
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 176.05
PB Ratio 10.26
Revenue 27.73M
Operating Income -229.16M
Net Income -215.81M
Free Cash Flow -182.74M
Net Cash 478.64M
Net Cash / Share 4.01
Gross Margin -601.23%
Operating Margin -826.48%
Profit Margin -778.30%
FCF Margin -659.07%
ROA -22.29%
ROE -44.16%
ROIC -41.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 7
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$42.50*
(3.86% upside)
Low
18.0
Current: $40.92
High
60.0
Target: 42.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue26.68129---
Revenue Growth-79.34%----
Gross Profit26.68129---
Operating Income-213-46.37-90.14-87.43-16.68
Net Income-198-36.24-88.19-86.65-16.79
Shares Outstanding95.6192.6214.966.423.01
Earnings Per Share-2.07-0.39-5.89-13.49-5.58
Operating Cash Flow-15250.12-76.64-71.91-15.05
Capital Expenditures-17.92-3.39-2.88-6.13-3.06
Free Cash Flow-16946.72-79.51-78.04-18.11
Cash & Equivalents41546440617830.74
Total Debt72.53----
Net Cash / Debt34346440617830.74
Assets55366248727136.68
Liabilities15811520.9316.554.01
Book Value395547466-94.15-15.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Denali Therapeutics Inc.
Country United States
Employees 276
CEO Ryan J. Watts

Stock Information

Ticker Symbol DNLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DNLI
IPO Date December 8, 2017

Description

Denali Therapeutics, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.